HSBC Holdings plc set a GBX 4,100 ($53.39) price target on AstraZeneca plc (LON:AZN) in a research note issued to investors on Tuesday. The firm currently has a sell rating on the biopharmaceutical company’s stock.
Other research analysts have also recently issued research reports about the company. UBS AG set a GBX 5,150 ($67.07) price target on AstraZeneca plc and gave the stock a neutral rating in a research report on Thursday, April 27th. Shore Capital restated a sell rating on shares of AstraZeneca plc in a research report on Wednesday, May 10th. J P Morgan Chase & Co restated a neutral rating on shares of AstraZeneca plc in a research report on Thursday, May 11th. Berenberg Bank raised their price target on AstraZeneca plc from GBX 5,670 ($73.84) to GBX 5,850 ($76.18) and gave the stock a buy rating in a research report on Wednesday, May 17th. Finally, Liberum Capital restated a buy rating and issued a GBX 5,500 ($71.62) price target on shares of AstraZeneca plc in a research report on Tuesday, May 23rd. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the stock. AstraZeneca plc has an average rating of Hold and a consensus target price of GBX 4,932.67 ($64.24).
Shares of AstraZeneca plc (LON:AZN) opened at 4384.00 on Tuesday. The stock has a 50 day moving average of GBX 4,929.68 and a 200 day moving average of GBX 4,859.79. The firm’s market cap is GBX 55.50 billion. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.
ILLEGAL ACTIVITY NOTICE: “AstraZeneca plc (LON:AZN) PT Set at GBX 4,100 by HSBC Holdings plc” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/08/12/astrazeneca-plc-lonazn-pt-set-at-gbx-4100-by-hsbc-holdings-plc.html.
The business also recently disclosed a dividend, which will be paid on Monday, September 11th. Investors of record on Thursday, August 10th will be paid a GBX 68.90 ($0.90) dividend. This represents a dividend yield of 1.35%. The ex-dividend date is Thursday, August 10th.
In related news, insider Nazneen Rahman acquired 39 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were bought at an average cost of GBX 4,370 ($56.91) per share, with a total value of £1,704.30 ($2,219.43).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.